No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals, 2 biggest deals this yr: $バーテックス ファーマシューティカルズ(VRTX.US)$paid $4.9 bil for$アルパイン イミューン サイエンシズ(ALPN.US)$ $ギリアド サイエンシズ(GILD.US)$paid $4.3 bil for $CBAY Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend... Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets, In the first four months of 2024 56% of M&A deal dollar went towards P...
$アルパイン イミューン サイエンシズ(ALPN.US)$ 🤩🤩🤩 SELL ALL IN APRIL AND TRAVEL (+ 💰💰💰💰💰) THEN SELL ALL AGAIN IN MAY (- $$$$$$ ) AND RUN AWAY 😭😭😭 47. G = Make Money From Thin Air, Block Short, Keep Repeating (Pump and Drop) to trap Buyers or Create Fake Symbols to Rob Money From Investors 47. T = Track and Kill by Weapons, Dark Magics, Nightmare, Accident, Sickness, Burn, Drown....them, and kill their children too, if they teach their children the same
$プロキドニー A(PROK.US)$sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days. PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news. Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday. ProKidney, which is trying t...
$プロキドニー A(PROK.US)$rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week. PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45. ProKidney has been soaring despite no news announcements, although the stock's rally began the day after$バーテックス ファーマシューティカルズ(VRTX.US)$unveiled plans to buy biotech$アルパイン イミューン サイエンシズ(ALPN.US)$for $4.9 ...
Morning Movers Gapping up $ナイキ B(NKE.US)$stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers. $アルパイン イミューン サイエンシズ(ALPN.US)$stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease. $レント ザ ランウェイ(RENT.US)$stock ju...
$バーテックス ファーマシューティカルズ(VRTX.US)$$アルパイン イミューン サイエンシズ(ALPN.US)$ ⚡ Vertex buys Alpine in a $4.9B deal 💰 ⇨ Acquisition for $65/sh or $4.9B in cash 🤑 ▪ Transaction closes in Q2 2024 ⇨ Includes ALPN lead product, povetacicep (ALPN-303) ▪ best-in-class potential in patients with IgA nephropathy ▪ Ph3 to initiate in H2 2024
アルパイン イミューン サイエンシズに関するコメント
Onconova Tx merger w/ Trawsfynydd Tx
$アディテクスト(ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $キンタラ セラピューティクス(KTRA.US)$
$ジョンソン エンド ジョンソン(JNJ.US)$ to acquire $ショックウェーブ メディカル(SWAV.US)$
$バーテックス ファーマシューティカルズ(VRTX.US)$ to acquire $アルパイン イミューン サイエンシズ(ALPN.US)$
$センチュリー セラピューティクス(IPSC.US)$ to acquire Clade Tx
$エリエム セラピューティクス(ELYM.US)$ to acquire Tenet Med.
$インサイト(INCY.US)$ to acquire Escient Pharm.
ONO Pharm to acquire $デシフィラ ファーマシューティカルズ(DCPH.US)$
...
2 biggest deals this yr:
$バーテックス ファーマシューティカルズ(VRTX.US)$ paid $4.9 bil for $アルパイン イミューン サイエンシズ(ALPN.US)$
$ギリアド サイエンシズ(GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
🤩🤩🤩 SELL ALL IN APRIL AND TRAVEL (+ 💰💰💰💰💰) THEN SELL ALL AGAIN IN MAY (- $$$$$$ ) AND RUN AWAY 😭😭😭
47. G = Make Money From Thin Air, Block Short, Keep Repeating (Pump and Drop) to trap Buyers or Create Fake Symbols to Rob Money From Investors
47. T = Track and Kill by Weapons, Dark Magics, Nightmare, Accident, Sickness, Burn, Drown....them, and kill their children too, if they teach their children the same
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $バーテックス ファーマシューティカルズ(VRTX.US)$ unveiled plans to buy biotech $アルパイン イミューン サイエンシズ(ALPN.US)$ for $4.9 ...
TuHURA Biosciences merger w/ $キンタラ セラピューティクス(KTRA.US)$
$ジョンソン エンド ジョンソン(JNJ.US)$ to acquire $ショックウェーブ メディカル(SWAV.US)$
$バーテックス ファーマシューティカルズ(VRTX.US)$ to acquire $アルパイン イミューン サイエンシズ(ALPN.US)$
What companies will be next? 🤔
Gapping up
$ナイキ B(NKE.US)$ stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers.
$アルパイン イミューン サイエンシズ(ALPN.US)$ stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease.
$レント ザ ランウェイ(RENT.US)$ stock ju...
⚡ Vertex buys Alpine in a $4.9B deal 💰
⇨ Acquisition for $65/sh or $4.9B in cash 🤑
▪ Transaction closes in Q2 2024
⇨ Includes ALPN lead product, povetacicep (ALPN-303)
▪ best-in-class potential in patients with IgA nephropathy
▪ Ph3 to initiate in H2 2024
まだコメントはありません